Skip to main content
. Author manuscript; available in PMC: 2019 Sep 11.
Published in final edited form as: Lab Chip. 2018 Sep 11;18(18):2787–2796. doi: 10.1039/c8lc00654g

Fig.6.

Fig.6.

Testing whether co-enzyme Q10 (CoQ10) can block cerivastatin–induced myopathy. a, the active force and (b) the specific active force (active force/diameter of myobundle) of myobundles under treatments of cerivastatin and CoQ10 for a week. All forces were normalized to day 8. (n=4–6, data presented as mean ±S.E.) mevalonate (* p < 0.05; ** p<0.01 relative to control conditions; c, Immunofluorescence staining of myobundles with sarcomeric α-actinin (SAA, red) and DAPI (blue), scale bar: 20μm. d, Oil-red O staining of myobundles under different treatments, scale bar: 50μm.